Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)
Mené en Suisse, cet essai randomisé de phase II analyse la survie, la qualité de vie, les fonctions neurocognitives de patients atteints de métastases cérébrales d'un cancer du poumon non à petites cellules et traités par une radiothérapie du cerveau entier combinée au géfitinib ou témozolomide
Patients with brain metastases (BM) rarely survive longer than 6months and are commonly excluded from clinical trials. We explored two combined modality regimens with novel agents with single agent activity and radiosensitizing properties. In this randomised phase II trial patients with BM from NSCLC were randomly assigned to 30Gy WBRT with either concomitant gefitinib (GFT) 250mg/day continuously or temozolomide (TMZ) 75mg/m2 for 21/28days. The primary end-point was overall survival, with quality of life and cognitive function as secondary end-points. We enrolled 59 patients (GFT 16, TMZ 43), and 56 patients have died, mainly (80%) from disease progression. Four patients succumbed complications of the disease or corticosteroids (intestinal perforation (2), CNS haemorrhage and pulmonary emboli). Median overall survival in the gefitinib arm was 6.3months (95% CI 2.1–14.6), and 4.9months (95% CI 2.3–5.6) in TMZ treated patients. Fatigue was the main complaint. No relevant toxicity with those therapeutic regimens was observed. Fatal outcome in three patients may have been related to corticosteroids. Cognitive function improved during treatment. However, median overall survival for all patients was only 4.9months (95% CI 2.3–5.7) and 1-year survival 25.4% (95% CI 15.4–37.0%).